Q3 2024 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) reported $71.7 million in total revenue for Q3 2024, driven by momentum in precision diagnostics, particularly in reproductive health and oncology.
- The company has initiated a Phase 2 clinical trial for FID-007, with encouraging preliminary results and plans to enroll approximately 40 patients.
- Fulgent Genetics Inc (FLGT) secured a significant contract with VA hospitals worth up to $99 million over five years for hereditary cancer and other germline tests.
- The company achieved MolDX approval for several hereditary cancer panels, expanding its portfolio of approved cancer tests.
- Fulgent Genetics Inc (FLGT) maintains a strong balance sheet with approximately $815.4 million in cash, cash equivalents, restricted cash, and marketable securities.
- Revenue decreased from $84.7 million in Q3 2023 to $71.7 million in Q3 2024, with negligible revenue from COVID-19 testing.
- The company recorded a $10.1 million impairment of available-for-sale debt securities, negatively impacting EPS by 33%.
- Non-GAAP operating margin was negative at minus 6%, despite improvements in gross margins.
- The therapeutic development business is expected to incur a cash burn of about $15 million to $17 million this year.
- The VA contract, while significant, will take time to scale, and revenue contributions are not expected to be evenly distributed over the five-year period.
Greetings, and welcome to the Fulgent Genetics Q3 2024 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to your host, Melanie Solomon, Investor Relations. Please go ahead.
Good morning, and welcome to the Fulgent third quarter 2024 financial results conference call. On the call today are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer.
The company's press release discussing the financial results is available on the Investor Relations section of the company's website, fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
